Work

Supplementary Table 3 from Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors

Year: 2023

Type: supplementary-materials

Abstract: . Inclusion and exclusion criteria for cohort 2d (advanced HER2-expressing non-breast/non-gastric or HER2-mutant solid tumors)

DOI: 10.1158/2159-8290.22535036.v1

Authors: Junji Tsurutani, Hiroji Iwata, Ian Krop, Pasi A. Jänne, Toshihiko Doi, Shunji Takahashi, Haeseong Park, Charles Redfern, Kenji Tamura, Trisha M. Wise-Draper, Kaku Saito, Masahiro Sugihara, Jasmeet Singh, Takahiro Jikoh, Gilles Gallant, Bob T. Li

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4362628518

Cites:

Cited by:

Related to: 10